About 6 results found for searched term "60-24-2" (0.114 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5366 | 4-Aminoantipyrine | COX |
| Ampyrone, NSC 60242 | ||
| 4-Aminoantipyrine(Ampyrone) is a metabolite of aminopyrine with analgesic, anti-inflammatory, and antipyretic properties. | ||
| M7994 | PRIMA-1 | p53 |
| NSC-281668 | ||
| PRIMA-1 is a selective re-activator of mutant p53 activity in tumor cells, and an inducer of apoptosis and inhibitor of growth of human tumors with mutant p53. | ||
| M8846 | VU0238429 | AChR/AChE |
| VU 0238429 | ||
| VU0238429 is a selective muscarinic acetylcholine receptor 5 (M5) positive allosteric modulator; causes leftward shift in acetylcholine potency. | ||
| M18563 | Ardisicrenoside A | Others |
| Ardisicrenoside A | ||
| M24827 | Talacotuzumab | IL Receptor/Related |
| JNJ 56022473; CSL 362 | ||
| Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models. | ||
| M49657 | LLL12 | STAT |
| LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
